eXoZymes, Inc. (EXOZ)

NASDAQ: EXOZ · Real-Time Price · USD
13.90
-0.10 (-0.71%)
May 29, 2025, 4:00 PM - Market closed
-0.71%
Market Cap 116.31M
Revenue (ttm) n/a
Net Income (ttm) -6.71M
Shares Out 8.37M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,963
Open 13.90
Previous Close 14.00
Day's Range 13.90 - 14.30
52-Week Range 8.50 - 23.99
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date May 12, 2025

About EXOZ

eXoZymes, Inc. a development stage company focused on building a technology platform that can develop assets that can be reapplied multiple times in different markets with only small changes, while maintaining and capturing new fundamental IP in the application. The company produces chemicals, including pharmaceuticals, fuels, materials, food additives, colors, fragrance and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The co... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 31
Stock Exchange NASDAQ
Ticker Symbol EXOZ
Full Company Profile

Financial Performance

Financial Statements

News

eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast

MONROVIA, CALIFORNIA / ACCESS Newswire / May 16, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceutical...

13 days ago - Accesswire

eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today

Management to host  earnings call at 5:00PM Eastern Time, today. MONROVIA, CA / ACCESS Newswire / May 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes th...

17 days ago - Accesswire

eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST

MONROVIA, CA / ACCESS Newswire / May 7, 2025 / eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, an...

22 days ago - Accesswire

eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health

N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier f...

23 days ago - Accesswire

Bringing clarity and precision to the cell-free space by introducing exozymes

Scientific definition of exozymes featured as cover story in GEN Biotechnology, freely available as an Open Access paper The author team introduces the terms ‘exozymes' to bring clarity to the rapidly...

5 weeks ago - GlobeNewsWire

BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant

Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, med...

7 weeks ago - GlobeNewsWire

eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus on...

2 months ago - GlobeNewsWire

eXoZymes Provides Fourth Quarter and Full Year 2024 Update

Management to Host Conference Call Today at 4:30PM Eastern

2 months ago - GlobeNewsWire

eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025

Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medi...

2 months ago - GlobeNewsWire

eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc.

Monrovia, CA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ, formerly Invizyne Technologies) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essentia...

3 months ago - GlobeNewsWire